Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma (TA1090)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 19 August 2025
Selective internal radiation therapies for treating hepatocellular carcinoma (TA688)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 3 July 2024Published: 31 March 2021
Image-guided percutaneous laser ablation for primary and secondary liver tumours (HTG722)Product type:GuidanceProgramme:HealthTech guidancePublished: 16 May 2024
Selective internal radiation therapy for neuroendocrine tumours that have metastasised to the liver (HTG720)Product type:GuidanceProgramme:HealthTech guidancePublished: 16 May 2024
Cabozantinib for previously treated advanced hepatocellular carcinoma (TA849)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 14 December 2022
Melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver (HTG575)Product type:GuidanceProgramme:HealthTech guidancePublished: 21 April 2021
Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma (TA666)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 16 December 2020
Selective internal radiation therapy for unresectable colorectal metastases in the liver (HTG542)Product type:GuidanceProgramme:HealthTech guidancePublished: 4 March 2020
Irreversible electroporation for primary liver cancer (HTG532)Product type:GuidanceProgramme:HealthTech guidancePublished: 27 November 2019
Ramucirumab for treating unresectable hepatocellular carcinoma after sorafenib (terminated appraisal) (TA609)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 30 October 2019
Regorafenib for previously treated advanced hepatocellular carcinoma (TA555)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 9 January 2019
Lenvatinib for untreated advanced hepatocellular carcinoma (TA551)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 19 December 2018
Selective internal radiation therapy for unresectable primary intrahepatic cholangiocarcinoma (HTG489)Product type:GuidanceProgramme:HealthTech guidancePublished: 31 October 2018
Sorafenib for treating advanced hepatocellular carcinoma (TA474)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 6 September 2017
Microwave ablation for treating liver metastases (HTG409)Product type:GuidanceProgramme:HealthTech guidancePublished: 27 April 2016
Living-donor liver transplantation (HTG390)Product type:GuidanceProgramme:HealthTech guidancePublished: 25 November 2015
Selective internal radiation therapy for primary hepatocellular carcinoma (HTG314)Product type:GuidanceProgramme:HealthTech guidancePublished: 23 July 2013
Irreversible electroporation for treating liver metastases (HTG304)Product type:GuidanceProgramme:HealthTech guidancePublished: 23 February 2013
SonoVue (sulphur hexafluoride microbubbles) – contrast agent for contrast-enhanced ultrasound imaging of the liver (HTG291)Product type:GuidanceProgramme:HealthTech guidancePublished: 29 August 2012
Radiofrequency ablation of hepatocellular carcinoma (HTG1)Product type:GuidanceProgramme:HealthTech guidancePublished: 23 July 2003